NASDAQ NMS - GLOBAL MARKET · PVLA
+1.83% · +$2.84 · Vol 182.3K
Market closed · last close 4:00 PM ET · price as of 16:00:58 ET
Palvella Therapeutics Inc

Palvella Therapeutics Inc

Biotechnology
$157.77
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
PVLA
Palvella Therapeutics Inc
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

43/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PVLA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PVLA catalysts
About Palvella Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
29
Country
US

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$159.00
Day high
$160.21
Day low
$156.09
Previous close
$154.93
52W high
$160.21
-1.52% from high
52W low
$40.90
98% of range
Market cap
$2.3B
EPS
$-4.6100
Beta
1.34
Shares out
14.4M
Volume
182.3K
0.69× rel vol
Avg volume
264K
VWAP
$158.25
Price history computed in-house
1W
+13.47%
1M
+4.46%
3M
+30.08%
1Y
+285.75%
YTD
+50.73%
SMA 50 $133.25 · above
SMA 200 $111.43 · above
52W position 98%

PVLA overview

Veridion Score
43
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PVLA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PVLA Form 4 filings
Public disclosures

Congress activity in PVLA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PVLA in the cached public ledger.

Federal contracts

PVLA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PVLA in this window.
Lobbying spend

PVLA lobbying filings, year to date.

Registered lobbying filings matched to Palvella Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PVLA in this window.
Loading news for PVLA
Analyst ratings
Sovereign unlock shows live analyst consensus for PVLA.
Options
Sovereign unlock shows live options positioning for PVLA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.